22157.jpg
World Metastatic Prostate Cancer Drug Landscape Research Report 2024: Comprehensive Insights about 90+ Companies and 110+ Pipeline Drugs
April 18, 2024 09:11 ET | Research and Markets
Dublin, April 18, 2024 (GLOBE NEWSWIRE) -- The "Metastatic Prostate Cancer - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.This report provides...
22157.jpg
Global PRMT5 Targeted Therapy Market & Clinical Trials Insights 2024: Innovation and Potential in Oncology and Beyond
February 29, 2024 04:06 ET | Research and Markets
Dublin, Feb. 29, 2024 (GLOBE NEWSWIRE) -- The "Global PRMT5 Targeted Therapy Market & Clinical Trials Opportunity Outlook 2024" report has been added to ResearchAndMarkets.com's offering. ...
Chinese Oncology Drugs Market
China Oncology Drugs Market Report, 2023 and 2024-2028 - Cancer Prevention Takes Center Stage in China's National Health Agenda
February 19, 2024 07:48 ET | Research and Markets
Dublin, Feb. 19, 2024 (GLOBE NEWSWIRE) -- The "China Oncology Drugs Market, Size, Forecast 2024-2028, Industry Trends, Share, Growth, Insight, Impact of Inflation, Company Analysis" report has been...
22157.jpg
Prostate Cancer Drugs Global Market Report 2024: Emerging Combination Therapies and Geographic Expansion to Propel the Global Prostate Cancer Drugs Market Through 2028
January 22, 2024 16:58 ET | Research and Markets
Dublin, Jan. 22, 2024 (GLOBE NEWSWIRE) -- The "Prostate Cancer Drugs Global Market Report 2024" report has been added to ResearchAndMarkets.com's offering. This recent comprehensive study sheds...
22157.jpg
Metastatic Prostate Cancer - Market Insight, Epidemiology And Market Forecast - 2032
January 04, 2024 18:33 ET | Research and Markets
Dublin, Jan. 04, 2024 (GLOBE NEWSWIRE) -- The "Metastatic Prostate Cancer - Market Insight, Epidemiology And Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This...
Global Prostate Cancer Drugs Market
Global Prostate Cancer Drugs Market Shows Robust Growth, Projected to Reach $23.50 Billion in 2027
July 24, 2023 05:08 ET | Research and Markets
Dublin, July 24, 2023 (GLOBE NEWSWIRE) -- The "Prostate Cancer Drugs Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering. The global prostate cancer drugs market...
Global Head And Neck Cancer Therapeutics Market
Head and Neck Cancer Therapeutics Global Market 2022: Sector to Reach $3.5 Billion by 2030 with APAC Being the Fastest Growing Region
February 23, 2023 05:23 ET | Research and Markets
Dublin, Feb. 23, 2023 (GLOBE NEWSWIRE) -- The "Head And Neck Cancer Therapeutics Market Size, Share & Trends Analysis Report By Therapy Type (Chemotherapy, Immunotherapy, Targeted Therapy), By...
Global Head and Neck Cancer Market
Global Head and Neck Cancer Therapeutics Market Report 2022: Advances in Biochemistry and Genomics Fuels Sector
September 16, 2022 08:23 ET | Research and Markets
Dublin, Sept. 16, 2022 (GLOBE NEWSWIRE) -- The "Head and Neck Cancer Therapeutics: Global Markets" report has been added to ResearchAndMarkets.com's offering. This report aims to provide a...
Nouveau Logo communiqué de presse.JPG
L’étude sur le TH1902 de Theratechnologies publiée dans la revue Pharmaceutics montre une inhibition de la croissance des cellules de type souches cancéreuses humaines du cancer de l’ovaire et du CSTN exprimant le récepteur de la sortiline (SORT1) et de la croissance tumorale
September 12, 2022 07:30 ET | Theratechnologies
Les chercheurs signalent une activité anticancéreuse supérieure contre les cellules de type souches cancéreuses avec le TH1902, comparativement au docétaxel non conjugué.Premières données probantes...
Nouveau Logo communiqué de presse.JPG
Theratechnologies TH1902 Study Published in Pharmaceutics Demonstrates Inhibition of Human Sortilin (SORT1)-Positive Ovarian and Triple-Negative Breast Cancer Stem-Like Cells and Tumor Growth
September 12, 2022 07:30 ET | Theratechnologies
Researchers report superior anticancer activity against cancer stem-like cells with TH1902, compared to unconjugated docetaxelFirst evidence for TH1902 targeting of human breast and ovarian cancer...